MX421834B - Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia - Google Patents
Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demenciaInfo
- Publication number
- MX421834B MX421834B MX2020008345A MX2020008345A MX421834B MX 421834 B MX421834 B MX 421834B MX 2020008345 A MX2020008345 A MX 2020008345A MX 2020008345 A MX2020008345 A MX 2020008345A MX 421834 B MX421834 B MX 421834B
- Authority
- MX
- Mexico
- Prior art keywords
- dementia
- adrenomedullin
- therapy
- adm
- prediction
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155682 | 2018-02-08 | ||
| PCT/EP2019/052982 WO2019154900A1 (en) | 2018-02-08 | 2019-02-07 | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020008345A MX2020008345A (es) | 2020-09-25 |
| MX421834B true MX421834B (es) | 2025-03-14 |
Family
ID=61188647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008345A MX421834B (es) | 2018-02-08 | 2019-02-07 | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210302440A1 (https=) |
| EP (1) | EP3749959A1 (https=) |
| JP (2) | JP2021513077A (https=) |
| KR (1) | KR102717599B1 (https=) |
| CN (2) | CN111902721B (https=) |
| AU (1) | AU2019219071A1 (https=) |
| BR (1) | BR112020014940A2 (https=) |
| CA (1) | CA3090736A1 (https=) |
| IL (1) | IL276564A (https=) |
| MX (1) | MX421834B (https=) |
| SG (1) | SG11202006686SA (https=) |
| WO (1) | WO2019154900A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220146538A (ko) | 2020-02-26 | 2022-11-01 | 페아엠 테라그노스틱스 게엠베하 | 치료 목적을 위한 펩티딜글리신 알파-아미드화 모노옥시게나제 (pam)의 용도 |
| CN115280148A (zh) | 2020-02-26 | 2022-11-01 | Pam治疗诊断有限公司 | 测定肽酰甘氨酸α-酰胺化单加氧酶(PAM)的方法及其用于诊断目的的用途 |
| EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
| CN120731367A (zh) | 2023-03-17 | 2025-09-30 | Pam治疗诊断有限公司 | 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途 |
| WO2025133203A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Compounds and methods for a long-lasting pam |
| WO2025133225A1 (en) | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam) |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| RU2004109222A (ru) | 2001-08-30 | 2005-10-20 | Байорексис Фармасьютикал Корпорейшн (Us) | Слитые белки модифицированного трансферрина |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US8278262B2 (en) | 2004-09-21 | 2012-10-02 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| DE102005036094A1 (de) * | 2005-08-01 | 2007-02-08 | B.R.A.H.M.S Ag | In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen |
| CA2620738C (en) | 2005-08-31 | 2010-10-12 | Ezaki Glico Co., Ltd. | Tablet for removing tongue coating |
| DE102006027818A1 (de) * | 2006-06-16 | 2007-12-20 | B.R.A.H.M.S. Aktiengesellschaft | In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen |
| DE102006060112A1 (de) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
| US20110039343A1 (en) * | 2008-02-01 | 2011-02-17 | Brahms Aktiengesellschaft | Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients |
| EP3785735A1 (en) | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| AU2010332932B2 (en) | 2009-12-14 | 2013-01-17 | Navigo Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin |
| RU2569745C2 (ru) | 2010-06-08 | 2015-11-27 | Пиерис АГ | Мутеины липокалина слезы, связывающие альфа il-4 r |
| FR2964103B1 (fr) * | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| DK2780717T3 (en) * | 2011-11-16 | 2017-02-13 | Sphingotec Gmbh | ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN |
| PL2594588T3 (pl) * | 2011-11-16 | 2014-11-28 | Adrenomed Ag | Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii |
| US20160230227A1 (en) * | 2012-12-21 | 2016-08-11 | The New York Stem Cell Foundation | Methods of treating alzheimer's disease |
| EP4231018A3 (en) * | 2016-07-08 | 2023-11-15 | SphingoTec GmbH | Adrenomedullin for assessing congestion in a subject with acute heart failure |
-
2019
- 2019-02-07 US US16/968,483 patent/US20210302440A1/en active Pending
- 2019-02-07 CA CA3090736A patent/CA3090736A1/en active Pending
- 2019-02-07 JP JP2020542645A patent/JP2021513077A/ja active Pending
- 2019-02-07 KR KR1020207025729A patent/KR102717599B1/ko active Active
- 2019-02-07 SG SG11202006686SA patent/SG11202006686SA/en unknown
- 2019-02-07 BR BR112020014940-3A patent/BR112020014940A2/pt not_active IP Right Cessation
- 2019-02-07 AU AU2019219071A patent/AU2019219071A1/en not_active Abandoned
- 2019-02-07 WO PCT/EP2019/052982 patent/WO2019154900A1/en not_active Ceased
- 2019-02-07 EP EP19702467.2A patent/EP3749959A1/en active Pending
- 2019-02-07 CN CN201980012542.1A patent/CN111902721B/zh active Active
- 2019-02-07 CN CN202411684173.XA patent/CN119770645A/zh active Pending
- 2019-02-07 MX MX2020008345A patent/MX421834B/es unknown
-
2020
- 2020-08-06 IL IL276564A patent/IL276564A/en unknown
-
2022
- 2022-12-30 US US18/148,633 patent/US20230221339A1/en active Pending
-
2023
- 2023-10-06 JP JP2023174585A patent/JP2024001208A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111902721B (zh) | 2024-12-13 |
| JP2024001208A (ja) | 2024-01-09 |
| US20230221339A1 (en) | 2023-07-13 |
| CA3090736A1 (en) | 2019-08-15 |
| KR102717599B1 (ko) | 2024-10-14 |
| SG11202006686SA (en) | 2020-08-28 |
| CN119770645A (zh) | 2025-04-08 |
| US20210302440A1 (en) | 2021-09-30 |
| JP2021513077A (ja) | 2021-05-20 |
| MX2020008345A (es) | 2020-09-25 |
| BR112020014940A2 (pt) | 2020-12-08 |
| RU2020129154A3 (https=) | 2022-03-10 |
| RU2020129154A (ru) | 2022-03-10 |
| KR20200135947A (ko) | 2020-12-04 |
| IL276564A (en) | 2020-09-30 |
| EP3749959A1 (en) | 2020-12-16 |
| WO2019154900A1 (en) | 2019-08-15 |
| AU2019219071A1 (en) | 2020-07-30 |
| CN111902721A (zh) | 2020-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX421834B (es) | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia | |
| WO2017070114A3 (en) | Diabetes-related biomarkers and treatment of diabetes-related conditions | |
| MX393482B (es) | Metodos para clasificar pacientes con un cancer solido | |
| CL2018003801A1 (es) | Protector auditivo con sensores de monitoreo de posición y sonido para evitar riesgos de sonido | |
| MX2020000604A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MY192558A (en) | Systems and methods for lte operation in unlicensed bands | |
| MX2016001854A (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento. | |
| EP3694464A4 (en) | SYSTEMS AND PROCEDURES FOR PREVENTION, RELIEF AND / OR TREATMENT OF DEMENTIA | |
| EP4582559A3 (en) | Biomarkers of traumatic brain injury | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| BR112017014134A2 (pt) | método de verificação de uma linha flexível e instalação para verificar uma linha flexível | |
| MX2015015605A (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| FR3023617B1 (fr) | Dispositif non invasif de determination de la fertilite et/ou du sexe d’un oeuf, et procede correspondant. | |
| HK1213892A1 (zh) | Tec家族激酶抑制剂疗法的伴随诊断 | |
| EP3804758A4 (en) | BIOMARKERS TO EVALUATE THE EFFECTIVENESS OF AN IMMUNE CHECKPOINT INHIBITOR | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| MX2016014408A (es) | Emulsion de agua en aceite para el cuidado de la piel. | |
| WO2016057702A3 (en) | Methods for prognosing and preventing metastatic liver disease | |
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| BR112019004913A2 (pt) | vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra | |
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| PH12019501092A1 (en) | Method of eveluating corrosion | |
| WO2019157527A3 (en) | Methods related to parkinson's disease and synucleinopathies | |
| MX2016009450A (es) | Ensayo novedoso para detectar periostina humana. | |
| NZ729773A (en) | Biomarkers for disease progression in melanoma |